Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen

Infection and Immunity

Volumn 74, Issue 1, 2006, Pages 773-776

  Polley, Rosalind ^a,d   Stager, Simona ^a,e   Prickett, Sara ^b,f   Maroof, Asher ^a,c   Zubairi, Soombul ^a,c   Smith, Deborah F ^b,c   Kaye, Paul M ^a,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e Johns Hopkins Singapore   (Singapore)

^f WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COGNATE ANTIGEN; CYTOKINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ARTICLE; BYSTANDER EFFECT; CD8+ T LYMPHOCYTE; EXPERIMENTAL INFECTION; IMMUNITY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY, ADOPTIVE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, TRANSGENIC; OVALBUMIN;

EID: 29644446928     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.74.1.773-776.2006     Document Type: Article

References (25)

1. Bathe, O. F., N. Dalyot-Herman, and T. R. Malek. 2001. IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy by persistent memory phenotypic CD8(+) T cells. J. Immunol. 167:4511-4517.
2. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168:3992-4000.
3. Berg, R. E., E. Crossley, S. Murray, and J. Forman. 2003. Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198:1583-1593.
4. Denny, P. W., S. Gokool, D. G. Russell, M. C. Field, and D. F. Smith. 2000. Acylation-dependent protein export in Leishmania. J. Biol. Chem. 275:11017-11025.
5. Houde, M., S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M. F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature 425:402-406.
6. Kamath, A. T., C. E. Sheasby, and D. F. Tough. 2005. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174:767-776.
7. Kaye, P. M., C. Coburn, M. McCrossan, and S. M. Beverley. 1993. Antigens targeted to the Leishmania phagolysosome are processed for CD4+ T cell recognition. Eur. J. Immunol. 23:2311-2319.
8. Kaye, P. M., A. Cooke, T. Lund, M. Wattie, and J. M. Blackwell. 1992. Altered course of visceral leishmaniasis in mice expressing transgenic I-E molecules. Eur. J. Immunol. 22:357-364.
9. Lertmemongkolchai, G., G. Cai, C. A. Hunter, and G. J. Bancroft. 2001. Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J. Immunol. 166:1097-1105.
10. Lopez, J. A., J. H. LeBowitz, S. M. Beverley, H. G. Rammensee, and P. Overath. 1993. Leishmania mexicana promastigotes induce cytotoxic T lymphocytes in vivo that do not recognize infected macrophages. Eur. J. Immunol. 23:217-223.
11. Misslitz, A., J. C. Mottram, P. Overath, and T. Aebischer. 2000. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol. Biochem. Parasitol. 107:251-261.
12. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777-785.
13. Muller, I., P. Kropf, J. A. Louis, and G. Milon. 1994. Expansion of gamma interferon-producing CD8+ T cells following secondary infection of mice immune to Leishmania major. Infect. Immun. 62:2575-2581.
14. Murray, H. W. 2005. Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J. Immunol. 174:4916-4923.
15. Polley, R., S. Zubairi, and P. M. Kaye. 2005. The fate of heterologous CD4+ T cells during Leishmania donovani infection. Eur. J. Immunol. 35:498-504.
16. +-T-Cell expansion and heterologous immunity. Infect. Immun. 73:7996-8001.
17. Saar, Y., A. Ransford, E. Waldman, S. Mazareb, S. Amin-Spector, J. Plumblee, S. J. Turco, and D. Zilberstein. 1998. Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol. Biochem. Parasitol. 95:9-20.
18. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712.
19. Stager, S., J. Alexander, A. C. Kirby, M. Botto, N. V. Rooijen, D. F. Smith, F. Brombacher, and P. M. Kaye. 2003. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat. Med. 9:1287-1292.
20. Stern, J. J., M. J. Oca, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1988. Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J. Immunol. 140:3971-3977.
21. Tsagozis, P., E. Karagouni, and E. Dotsika. 2003. CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 25:569-579.
22. Tsagozis, P., E. Karagouni, and E. Dotsika. 2005. Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis. Parasitol. Int. 54:139-146.
23. Wang, Z. E., S. L. Reiner, F. Hatam, F. P. Heinzel, J. Bouvier, C. W. Turck, and R. M. Locksley. 1993. Targeted activation of CD8 cells and infection of beta 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J. Immunol. 151:2077-2086.
24. Weninger, W., M. A. Crowley, N. Manjunath, and U. H. von Andrian. 2001. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194:953-966.
25. Zubairi, S., S. L. Sanos, S. Hill, and P. M. Kaye. 2004. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 34:1433-1440.